Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Asep Medical Holdings Inc C.ASEP

Alternate Symbol(s):  SEPSF

ASEP Medical Holdings Inc. is a Canada-based company, which is in the business of acquiring research and development assets, technologies and/or businesses in the area of life sciences and medical diagnostics. The Company’s consolidates three development-stage companies, including Sepset Biosciences Inc., ABT Innovations Inc., and SafeCoat Medical Inc. It provides medical devices with an anti-microbial, antifouling coating through its SafeCoat Medical Inc. The Company also provides diagnostic kits for predicting the onset of severe Sepsis and organ failure through its Sepset Biosciences Inc. The Company also offers peptide technology through its ABT Innovations Inc. Its technology includes diagnostic and therapeutic. It has developed a novel diagnostic assay for the early and rapid diagnosis of sepsis, based on the detection of molecular signatures of sepsis specific to the immune response, rather than the presence of a pathogen.


CSE:ASEP - Post by User

Post by waves1on Nov 25, 2021 6:42pm
79 Views
Post# 34166864

2022 Commercialization of tests will be a massive catalyst

2022 Commercialization of tests will be a massive catalyst
More information on sepsis and the dire need for an improved way to diagnose and treat it.
 
Sepsis is one of the most prevalent causes of death in the US and current industry tests require 24 hours for results to detect and confirm Sepsis.
 
I'm expecting that the mid-2022 commercialization of ASEP Medical Holdings ($ASEP $ASEP.CN)'s tests will be a massive catalyst for the stock. 
 
The ability of the tests to be used to both treat and prevent sepsis by detecting a unique gene expression is going to be a revolutionary step for medicine. 
 
https://www.jems.com/patient-care/improving-outcomes-in-sepsis/  
<< Previous
Bullboard Posts
Next >>